Genetic and pharmacokinetic factors affecting the initial pharmacotherapeutic effect of paroxetine in Japanese patients with panic disorder

European Journal of Clinical Pharmacology

Volumn 65, Issue 7, 2009, Pages 685-691

  Saeki, Yoshinori ^a   Watanabe, Takashi ^a   Ueda, Mikito ^a   Saito, Atsushi ^a   Akiyama, Kazufumi ^a   Inoue, Yoshimasa ^b   Hirokane, Genta ^c   Morita, Sachiyo ^c   Yamada, Naoto ^c   Shimoda, Kazutaka ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b MP Technopharma Corporation Technology Department   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

5 HTTLPR; Panic disorder; Paroxetine; Pharmacotherapy; SSRIs

Indexed keywords

BROTIZOLAM; GENOMIC DNA; LORAZEPAM; PAROXETINE; SEROTONIN TRANSPORTER;

ABNORMAL SENSATION; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMORBIDITY; DISEASE SEVERITY; DNA POLYMORPHISM; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSOMNIA; JAPANESE; LOW DRUG DOSE; MALE; OUTCOME ASSESSMENT; PANIC; PHARMACOGENETICS; PHYSICAL DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RATING SCALE; SCORING SYSTEM;

ADULT; AGED; AGORAPHOBIA; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; JAPAN; LINEAR MODELS; MALE; MIDDLE AGED; PANIC DISORDER; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 67649117884     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0633-8     Document Type: Article

References (37)

1. MM Weissman RC Bland GJ Canino C Faravelli S Greenwald HG Hwu PR Joyce EG Karam CK Lee J Lellouch JP Lepine SC Newman MA Oakley-Browne M Rubio-Stipec JE Wells PJ Wickramaratne HU Wittchen EK Yeh 1997 The cross-national epidemiology of panic disorder Arch Gen Psychiatry 54 305 309 (Pubitemid 27171915)
2. P Carlbring H Gustafsson L Ekselius G Andersson 2002 12-month prevalence of panic disorder with or without agoraphobia in the Swedish general population Soc Psychiatry Psychiatr Epidemiol 37 207 211 (Pubitemid 36067953)
3. RR Crowe R Noyes DL Pauls D Slymen 1983 A family study of panic disorder Arch Gen Psychiatry 40 065 1069
4. EL Harris R Noyes Jr RR Crowe DR Chaudhry 1983 Family study of agoraphobia. Report of a pilot study Arch Gen Psychiatry 40 1061 1064
5. I Skre S Onstad S Torgersen S Lygren E Kringlen 1993 A twin study of DSM-III-R anxiety disorders Acta Psychiatr Scand 88 85 92 (Pubitemid 23225827)
6. JM Hettema MC Neale KS Kendler 2001 A review and meta-analysis of the genetic epidemiology of anxiety disorders Am J Psychiatry 158 1568 1578 (Pubitemid 32923644)
7. S Oehrberg PE Christiansen K Behnke AL Borup B Severin J Soegaard H Calberg R Judge JK Ohrstrom PM Manniche 1995 Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study Br J Psychiatry 167 374 379 (Pubitemid 26197752)
8. Y Lecrubier A Bakker G Dunbar R Judge 1997 A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators Acta Psychiatr Scand 95 145 152
9. Y Lecrubier R Judge 1997 Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators Acta Psychiatr Scand 95 153 160
10. JC Ballenger DE Wheadon M Steiner W Bushnell IP Gergel 1998 Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder Am J Psychiatry 155 36 42 (Pubitemid 28037546)
11. DW Black R Wesner W Bowers J Gabel 1993 A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder Arch Gen Psychiatry 50 44 50 (Pubitemid 23026988)
12. J Sandmann B Lorch B Bandelow S Hartter P Winter C Hiemke O Benkert 1998 Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine Pharmacopsychiatry 31 117 121 (Pubitemid 28399079)
13. T Watanabe M Ueda Y Saeki G Hirokane S Morita M Okawa K Akiyama K Shimoda 2007 High plasma concentrations of paroxetine impede clinical response in patients with panic disorder Ther Drug Monit 29 40 44 (Pubitemid 46279874)
14. JH Meyer AA Wilson N Ginovart V Goulding D Hussey K Hood S Houle 2001 Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study Am J Psychiatry 158 1843 1849 (Pubitemid 33054777)
15. KP Lesch D Bengel A Heils SZ Sabol BD Greenberg S Petri J Benjamin CR Muller DH Hamer DL Murphy 1996 Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region Science 274 1527 1531 (Pubitemid 26403928)
16. A Heils A Teufel S Petri G Stober P Riederer D Bengel KP Lesch 1996 Allelic variation of human serotonin transporter gene expression J Neurochem 66 2621 2624 (Pubitemid 26159101)
17. J Deckert M Catalano A Heils D Di Bella F Friess E Politi P Franke MM Nothen W Maier L Bellodi KP Lesch 1997 Functional promoter polymorphism of the human serotonin transporter: lack of association with panic disorder Psychiatr Genet 7 45 47 (Pubitemid 27356821)
18. SP Hamilton GA Heiman F Haghighi S Mick DF Klein SE Hodge MM Weissman AJ Fyer JA Knowles 1999 Lack of genetic linkage or association between a functional serotonin transporter polymorphism and panic disorder Psychiatr Genet 9 1 6
19. H Ishiguro T Arinami K Yamada Y Otsuka M Toru H Shibuya 1997 An association study between a transcriptional polymorphism in the serotonin transporter gene and panic disorder in a Japanese population Psychiatry Clin Neurosci 51 333 335 (Pubitemid 27463158)
20. OF Olesen B Bennike ES Hansen P Koefoed DP Woldbye TG Bolwig E Mellerup 2005 The short/long polymorphism in the serotonin transporter gene promoter is not associated with panic disorder in a Scandinavian sample Psychiatr Genet 15 159 (Pubitemid 41231935)
21. G Perna E Favaron D Di Bella R Bussi L Bellodi 2005 Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene Neuropsychopharmacology 30 2230 2235 (Pubitemid 41643974)
22. B Bandelow 1995 Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale Int Clin Psychopharmacol 10 73 81
23. C Charlier F Broly M Lhermitte E Pinto M Ansseau G Plomteux 2003 Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine Ther Drug Monit 25 738 742 (Pubitemid 37499310)
24. C Güzey T Aamo O Spigset 2000 Risperidone metabolism and the impact of being a cytochrome P450 2D6 ultrarapid metabolizer J Clin Psychiatry 61 600 601 (Pubitemid 30677977)
25. Y Nishida T Fukuda I Yamamoto J Azuma 2000 CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10 Pharmacogenetics 10 567 570 (Pubitemid 30702912)
26. K Hikida Y Inoue E Nouchi Y Ohkura 1990 Determination of etizolam in human serum or plasma using automated column-switching high-performance liquid chromatography Jpn J Clin Chem 19 354 359
27. Stahl SM (2000) Essential psychopharmacology, 2nd ed. Cambridge University Press, New York
28. AK Louie TB Lewis RA Lannon 1993 Use of low-dose fluoxetine in major depression and panic disorder J Clin Psychiatry 54 435 438 (Pubitemid 24020599)
29. M Gilles M Deuschle S Kellner M Shams B Krumm S Hartter I Heuser C Hiemke 2005 Paroxetine serum concentrations in depressed patients and response to treatment Pharmacopsychiatry 38 118 121 (Pubitemid 40965963)
30. SM Stahl 2002 Independent actions on fear circuits may lead to therapeutic synergy for anxiety when combining serotonergic and GABAergic agents J Clin Psychiatry 63 854 855 (Pubitemid 35231724)
31. SP David NV Murthy EA Rabiner MR Munafo EC Johnstone R Jacob RT Walton PM Grasby 2005 A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1A receptor binding in humans J Neurosci 25 2586 2590 (Pubitemid 40365170)
32. NM Simon D Fischmann 2005 The implications of medical and psychiatric comorbidity with panic disorder J Clin Psychiatry 66 Suppl 4 8 15 (Pubitemid 40637720)
33. GM Murphy Jr SB Hollander HE Rodrigues C Kremer AF Schatzberg 2004 Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression Arch Gen Psychiatry 61 1163 1169 (Pubitemid 39463418)
34. RH Perlis D Mischoulon JW Smoller YJ Wan S Lamon-Fava KM Lin JF Rosenbaum M Fava 2003 Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment Biol Psychiatry 54 879 883 (Pubitemid 37311349)
35. H Takahashi K Yoshida K Ito K Sato M Kamata H Higuchi T Shimizu K Ito K Inoue T Tezuka T Suzuki T Ohkubo K Sugawara 2002 No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment Eur Neuropsychopharmacol 12 477 481
36. M Kato T Fukuda M Wakeno K Fukuda G Okugawa Y Ikenaga M Yamashita Y Takekita K Nobuhara J Azuma T Kinoshita 2006 Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients Neuropsychobiology 53 186 195 (Pubitemid 44252779)
37. C Blaya GA Salum MS Lima S Leistner-Segal GG Manfro 2007 Lack of association between the serotonin transporter promoter polymorphism (5-HTTLPR) and panic disorder: a systematic review and meta-analysis Behav Brain Funct 3 41